Gender difference in ifosfamide metabolism by human liver microsomes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 3, 2001, Pages 193-200

  Schmidt, R ^a   Baumann, F ^a   Hanschmann, H ^a   Geissler, F ^a   Preiss, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Clinical implications; Gender differencce; Ifosfamide 4 hydroxylation and N Dechloroethylation

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; IFOSFAMIDE;

ADULT; AGED; ALKYLATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NEUROTOXICITY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL MARKERS; BIOTRANSFORMATION; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROXYLATION; IFOSFAMIDE; ISOENZYMES; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; SEX CHARACTERISTICS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0034779879     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190396     Document Type: Article

References (33)

1. Gender-related differences in pharmacokinetics and their significance
2. Gender differences in pharmacokinetics
3. Demographic factors affecting the pharmacokinetics of cydosporine estimated by radioimmunoassay
4. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics
5. Intersubject and dose-related variability after intravenous administration of erythromycin
6. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
7. Effect of age and gender on the activity of human hepatic CYP3A
8. Gender differences in pharmacokinetics and pharmacodynamics
9. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes
10. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway
11. Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide
12. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo
13. Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
14. Identification of the major human hepatic ccytochrome P450 involved in activation and N-dechloroethylation of ifosfamide
15. Stereoselective metabolism of ifosfamide by human P450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer
16. Role of CYP2B6 and CYP3A4 in the vitro N-dechloroethylation of (R)and (S)-ifosfamide in human liver microsomes
17. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the prinziple of protein-dye binding
18. The carbon monoxide-binding pigment of liver microsomes
19. Identificationn of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity
20. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
21. Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites
22. Cytochrome P450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat
23. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide inn mice
24. Gender effects in pharmacokinetics and pharmacodynamics
25. Gender differences in psychotropic drug metabolism
26. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
27. Pharmacokinetics and bioavailability of oral ifosfamide
28. Oral ifosfamide-mesna: A clinical investigation in advanced non-small cell lung cancer
29. Ifosfamide extrapyramidal neurotoxicity
30. Hallucinations and ifosfamide-induced neurotoxicity
31. Encephalopathy in ifosfamide-treated patients
32. Ifosfamide encephalopathy: A reappraisal
33. Methylene blue and the neurotoxic mechanisms of ifosfamide enccephalopathy